Zhixing Financial APP News, Tibet Weixinkang Pharmaceutical (603676.SH) released the quarterly report for the first three quarters of 2024. During the reporting period, the company's revenue was 0.994 billion yuan, a decrease of 6.30% year-on-year; net income attributable to shareholders of the listed company was 0.243 billion yuan, an increase of 15.71% year-on-year; after deducting non-recurring gains and losses, net income attributable to shareholders of the listed company was 0.197 billion yuan, an increase of 15.84% year-on-year; basic earnings per share were 0.56 yuan/share.